Jump to content

Dicycloplatin

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CitationCleanerBot (talk | contribs) at 00:25, 8 November 2016 (→top: clean up, url redundant with pmc, add pmc, and/or remove accessdate if no url using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Dicycloplatin or DCP is a Phase I clinical cancer drug which is derived from carboplatin and 1,1-cyclobutane dicarboxylate.[1] It has higher solubility and higher stability in comparison with the carboplatin.[2]

See also

References

  1. ^ Apps, M. G.; Choi, E. H. Y.; Wheate, N. J. (2015). "The state-of-play and future of platinum drugs". Endocrine-related Cancer. 22 (4): 219–233. doi:10.1530/ERC-15-0237. PMID 26113607.
  2. ^ Yu JJ, Yang X, Song Q, Mueller MD, Remick SC (Jan 2014). "Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies". Anticancer Res. 34 (1): 455–63. doi:10.5414/CP201761. PMID 24403501.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Dicycloplatin&oldid=748394684"